

Publications auxquelles l'Aretasc a participé 2016

- 1- DPYD genotyping to predict adverse events following treatment with fluorouracil- based adjuvant chemotherapy in patients with stage III colon cancer ; A secondary analysis of the PETACC 8 randomized clinical trial .
Boige V, Vincent M, Alexandre P : JAMA Oncol 2016 Jan 2 & . doi : 10.1001

- 2 - Prognostic effect of BRAF and KRAS Mutations in patients with stage III colon cancer treated with leucovorin fluorouracil and oxaliplatin with or without cetuximab A post hoc analysis of the PETACC-8 trial.
Taieb J, Zaanan A, Le Malicot K. JAMA Oncol 2016 Jan 15

- 3- primary analysis of the EORTC 1004/BIG 3-04 MINDACT study : A prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical and pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. M. Piccart, E. Rutgers S. Delage ; AACR , April 8, 2016

- 4- long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer BCRIG-005 randomized trial. Mockett JR, Pienkowski T, Crown J
Ann Oncol (2016) 27(6) :1041-1047 doi : 10.1093/annonc/mdw 098.

- 5 Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
The Lancet Oncology [Volume 17, No. 6](#), p747–756, June 2016